Opendata, web and dolomites

NeuroProtect

Novel Drug Therapy with Potential to Cure Neuro-Degenerative Diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NeuroProtect project word cloud

Explore the words cloud of the NeuroProtect project. It provides you a very rough idea of what is the project "NeuroProtect" about.

outlicense    neuro    ip    compound    remarkable    apoptotic    select    sclerosis    route    clinical    fastest    companies    investors    primary    ad    total    socioeconomic    advisors    dong    showed    led    refund    anti    physician    hp    natural    significance    relatively    faster    human    strategy    patient    lateral    economic    finish    lifetime    rare    europeans    pd    reverse    neurodegenerative    proven    company    diseases    update    extensive    team    gives    drugs    until    japan    whilst    worked    pay    mouse    game    perform    market    over    parkinson    300m    herb    guan    industry    reduce    dr    neuronal    switzerland    founders    david    suffer    therapies    symptoms    neurons    trials    honeywell    vitro    succeed    preliminary    standard    10m    global    damaged    multinational    phase    efficiency    orphan    yuhong    approval    treat    co    axon    amyotrophic    business    plan    neuroprotect    models    planning    positions    changer    alone    commercialization    pharma    neuroprotective    cure    outgrowth    15m    royalties    disease    alzheimer    healing    rescuing    pharmaceutical    als    tests    drug    burden   

Project "NeuroProtect" data sheet

The following table provides information about the project.

Coordinator
SUNREGEN HEALTHCARE AG 

Organization address
address: ROBINIENWEG 51
city: Reinach
postcode: 4153
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website http://www.sunregen.ch
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SUNREGEN HEALTHCARE AG CH (Reinach) coordinator 50˙000.00

Map

 Project objective

Over 10M Europeans suffer from neurodegenerative diseases such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD) and Amyotrophic Lateral Sclerosis (ALS). Whilst there are many drugs that treat symptoms of these diseases, there are no therapies that can reverse or cure them. Our novel compound NeuroProtect has the potential to be a game changer by healing damaged neurons. NeuroProtect is a natural herb-derived compound with remarkable neuroprotective, neuro-rescuing, anti-apoptotic, and axon-outgrowth effects in mouse primary neuronal and human neuronal models. We have proven the compound’s efficiency in preliminary in-vitro tests. To take NeuroProtect to market fastest, we will focus on ALS that where we can use the orphan drug route and get clinical approval faster. This gives us an immediate target market of €300M per year in Europe, the US, Japan and Switzerland alone. Although ALS is relatively rare, the socioeconomic significance of the disease is extensive: a recent study showed that total lifetime costs for ALS were €1.15M per patient. NeuroProtect can therefore contribute to reduce the global economic burden of ALS. We are planning to take the standard route for commercialization in pharma industry: take the compound through pre-clinical studies, Phase I and Phase II clinical trials and then outlicense to a large pharma company who will refund our cost until they finish the Phase III trials and then pay us royalties. Our team is led by two experienced co-founders: Dr. Yuhong Dong, who has worked for a multinational pharmaceutical company for over 10 years as well as a physician for 4 years, and David Guan, who has over 10 years of management positions at multinational companies (HP, Honeywell). We are also supported by experienced advisors and investors to help us succeed. We are planning to use the Phase 1 funding to select our pre-clinical study partners, perform a market assessment, assess our IP strategy and update our business plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEUROPROTECT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEUROPROTECT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More